Xoma and Inveready acquires royalty interest position in six clinical-stage assets from Palobiofarma
1/10/2019 Nota de prensa XOMA AND INVEREADY ACQUIRES ROYALTY INTEREST POSITION IN SIX CLINICAL-STAGE ASSETS FROM PALOBIOFARMA. XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.One of the assets, NIR178, is being developed by Novartis as a…